WHO ICTRP trial
Outcome of patient receiving additional chemotherapy after chemoradiotherapy for…
CTRI/2021/05/033642 · Clinical Trials Registry India (CTRI) · Recruiting
Key facts
| Trial ID | CTRI/2021/05/033642 |
|---|---|
| Public title | Outcome of patient receiving additional chemotherapy after chemoradiotherapy for locally advanced rectal carcinoma compared to those receiving only chemoradiotherapy |
| Scientific title | Total Neoadjuvant Therapy for Locally Advanced Rectal Carcinoma: A Multicentric Randomized Controlled Trial - TNT-LARC |
| Primary sponsor | Medical College Kolkata |
| Registry | Clinical Trials Registry India (CTRI) |
| Recruitment status | Recruiting |
| Study type | Interventional |
| Phase | Phase 3/ Phase 4 |
| Countries | India |
| Conditions | Health Condition 1: C20- Malignant neoplasm of rectum |
| Interventions | Intervention1: Chemoradiotherapy followed by Capecitabine and oxaliplatin: Three cycles of Capecitabine and Oxaliplatin will be administered 2 weeks after completion of neoadjuvant chemoradiotherapy (50.4 Gy radiation with Capecitabine-825… |
| Registration date | May 17, 2021 |
| Target size | 258 |
| Secondary IDs | NIL |
| Registry page | ctri.nic.in |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: